News

Price Target

Analyst Ratings

Cantor Fitzgerald Maintains Overweight on Exagen, Lowers Price Target to $7

Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is riding its strongest rally in two years &#8211; and now, it's firing on all cylinders with a fresh catalyst: a <a href="https://www.benzinga.com//node/45410939">$6 billion stock buyback plan</a>. 
The announcement, coupled with a string of recent wins, has sent AMD shares soaring over 21% in the past month.
<h2 class="wp-block-heading">AMD Stock Technical Breakout In Progress</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM.png" alt="" class="wp-image-916673" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
AMD has broken past resistance at around $115 and is charging toward its 200-day simple moving average (SMA) of $127.18. With the stock trading above its five, 20, and 50-day exponential moving averages, technical signals remain bullish. 
The MACD (moving average convergence/divergence) indicator at 4.4 suggests continued buying strength, though the RSI (relative strength index) sitting at the cusp of overbought conditions at 70, flags near-term caution.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM.png" alt="" class="wp-image-916675" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Shorter-term indicators still support the momentum. The eight-day SMA at $107.24, the 20-day at $99.23, and the 50-day at $99.21 all sit well below the current price &#8211; reinforcing the trend strength. 
However, the stock has not yet cleared the 200-day SMA, which could act as a crucial test in coming sessions.
Read Also: <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules</a>
<h2 class="wp-block-heading">Buybacks, Big Deals, And Beating Expectations</h2>
The buyback boost brings AMD's total repurchase firepower to $10 billion, thanks to the existing $4 billion balance from a prior authorization. With $7.31 billion in cash on hand, AMD has room to keep rewarding shareholders.
Momentum has been building fast: the company recently posted first quarter earnings that beat expectations &#8211; $7.44 billion in revenue and 96 cents in adjusted EPS, topping estimates of $7.13 billion and 94 cents, respectively. It also announced a $10 billion data center deal in Saudi Arabia and inked a GPU cluster partnership with TensorWave.
From technical breakout to buyback buzz, AMD's rally has legs &#8211; and the bulls don't seem ready to let go just yet.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45437643/nvidia-now-worth-35x-intel-after-16-year-surge-and-valuation-gap-keeps-growing">Nvidia Now Worth 35x Intel After 16-Year Surge And Valuation Gap Keeps Growing</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Technicals

Tech

Trading Ideas

Best AMD Stock Rally In 2 Years Gets A Buyback Boost

Rosenblatt analyst Blair Abernethy maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Buy and maintains $67 price target.

Rosenblatt Maintains Buy on Dynatrace, Maintains $67 Price Target

Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) with a Buy and maintains $33 price target.

ADVM

Chardan Capital Maintains Buy on Adverum Biotechnologies, Maintains $33 Price Target

<a href="https://www.wsj.com/health/pharma/new-allegations-about-timing-of-pfizer-covid-vaccine-passed-to-house-panel-3451ec97?msockid=21c662101c496b42343370ae1de86aaa">https://www.wsj.com/health/pharma/new-allegations-about-timing-of-pfizer-covid-vaccine-passed-to-house-panel-3451ec97?msockid=21c662101c496b42343370ae1de86aaa</a>

General

'New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel'- WSJ

Cantor Fitzgerald analyst Deepak Mathivanan reiterates Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and maintains $170 price target.

Reiteration

EXPE

Cantor Fitzgerald Reiterates Neutral on Expedia Group, Maintains $170 Price Target

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock is trading lower on Thursday in reaction to a media report on a possible investigation for <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45426769/unitedhealth-stock-plunges-over-8-in-after-hours-trading-as-doj-criminal-probe-adds-to-turmoil-after-ceo-shake-up" rel="noreferrer noopener">criminal Medicare fraud</a>.
The Wall Street Journal <a href="https://www.wsj.com/us-news/unitedhealth-medicare-fraud-investigation-df80667f?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo">reported</a>, citing people familiar with the matter, that the healthcare-fraud unit of the Justice Department&#8217;s criminal division is overseeing the investigation, which has been active since at least last summer. 
UnitedHealth&#8217;s latest annual securities filing says the company &#8220;has been involved or is currently involved in various governmental investigations, audits and reviews,&#8221; and flags involved agencies including the Justice Department. 
It doesn&#8217;t specifically mention the criminal, civil and antitrust probes on which the Journal has reported.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44821140/unitedhealth-demands-rapid-repayment-of-cyberattack-relief-loan-billions-providers-say-push-undermines-recovery" rel="noreferrer noopener">UnitedHealth Demands Rapid Repayment Of Cyberattack Relief Loan Billions, Providers Say Push Undermines Recovery</a>
In a statement on Wednesday, the company <a target="_blank" href="https://www.unitedhealthgroup.com/newsroom/2025/2025-05-14-response-may-14-wsj-article.html" rel="noreferrer noopener">said</a>, &#8220;We have not been notified by the Department of Justice of the supposed criminal investigation reported, without official attribution, in the&nbsp;Wall Street Journal today.&#8221;
&#8220;We stand by the integrity of our Medicare Advantage program,&#8221; the company statement continued.
On Tuesday, UnitedHealth CEO Andrew Witty abruptly announced his resignation and suspended its <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" target="_blank" rel="noreferrer noopener">fiscal year 2025 guidance</a>.
The insurance giant has garnered immense attention following the murder of its insurance unit CEO,&nbsp;Brian Thompson, in New York.
Luigi Mangione, the alleged perpetrator, pleaded not guilty to murder and weapons charges. Police found shell casings at the scene with the words &#8220;deny,&#8221; &#8220;defend,&#8221; and &#8220;depose,&#8221; commonly associated with insurance industry strategies for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42771908/viral-tear-it-all-down-post-sparks-debate-over-unitedhealthcare-practices-alleges-denial-of-icu-care-for-comatose-patient" rel="noreferrer noopener">handling claims and disputes</a>.
According to a media report in February, the Justice Department reportedly launched a civil fraud investigation into&nbsp;UnitedHealth&#8217;s <a target="_blank" href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" rel="noreferrer noopener">Medicare billing practices</a>.
The WSJ&nbsp;<a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-medicare-doj-diagnosis-investigation-66b9f1db?mod=latest_headlines&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">reported</a>&nbsp;that Medicare paid substantial sums to UnitedHealth based on diagnoses added to patients&#8217; records, some of which doctors said were irrelevant or undocumented.
In March, a Special Master recommended granting&nbsp;UnitedHealth&#8217;s&nbsp;motion for summary judgment in a False Claims Act (FCA) case, concluding that the government lacks evidence&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44141489/false-claims-act-case-against-unitedhealth-faces-dismissal-recommendation" rel="noreferrer noopener">to support its allegations</a>.
In April, UnitedHealth got some relief when the Federal Trade Commission (FTC) paused the formal complaint against three major pharmacy benefit managers (PBMs) for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">price of insulin medications</a>.
Analyst Reaction:
<ul class="wp-block-list">
<li>Keybanc maintains UnitedHealth with an Overweight rating, lowering the <a href="https://www.benzinga.com/quote/UNH/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $575 to $450</a>.</li>
<li>Baird maintains UnitedHealth with an Outperform rating, lowering the price target from $510 to $356.</li>
<li>BofA Securities downgrades UnitedHealth from Buy to Neutral and lowers the price target from $560 to $350.</li>
<li>Morgan Stanley maintains UnitedHealth with an Overweight rating, lowering the price target from $563 to $374.</li>
<li>Wells Fargo maintains UnitedHealth with an Overweight, lowering the price target from $677 to $351.</li>
<li>Oppenheimer maintains UnitedHealth with an Outperform rating, lowering the price target from $600 to $400.</li>
<li>Deutsche Bank maintains UnitedHealth with a Buy, lowering the price target from $521 to $362.</li>
<li>JP Morgan maintains UnitedHealth with an Overweight, lowering the price target from $525 to $405.</li>
</ul>
Price Action: UnitedHealth stock is down 7.83% at $283.88 during the premarket session at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45435748/dicks-sporting-goods-to-acquire-foot-locker-at-66-premium" target="_blank" rel="noreferrer noopener">Dick&#8217;s Sporting Goods To Acquire Foot Locker At 66% Premium</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Legal

Movers

Why Is UnitedHealth Stock Trading Lower On Thursday?

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) with a Buy and maintains $20 price target.

SABS

Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $20 Price Target

US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) has outperformed the market over the past 5 years by 17.53% on an annualized basis producing an average annual return of 32.55%. Currently, US Foods Hldg has a market capitalization of $17.33 billion. 
Buying $1000 In USFD: If an investor had bought $1000 of USFD stock 5 years ago, it would be worth $3,907.86 today based on a price of $74.91 for USFD at the time of writing.
<h3>US Foods Hldg's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747323016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

USFD

Here's How Much You Would Have Made Owning US Foods Hldg Stock In The Last 5 Years

Cantor Fitzgerald analyst Ross Osborn reiterates Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Overweight and maintains $2 price target.

LUCD

Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $2 Price Target

Cantor Fitzgerald analyst Kristen Kluska upgrades Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) from Neutral to Overweight and announces $10 price target.

Upgrades

FULC

Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight, Announces $10 Price Target

WIIM

CNEY

CN Energy Group shares are trading lower after the company reported a 1-for-25 reverse stock split.

Reddit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NASDAQ">RDDT</a>) shares fell 9.4% to $113.55 on Thursday, pulling back after a recent rally that had lifted the stock more than 25% over the past month. The decline follows a 9.2% jump on Wednesday, fueled by the company's strong <a href="https://www.benzinga.com/general/social-media/25/05/45178546/reddit-executives-see-strong-growth-in-q2-and-beyond">first-quarter earnings</a> and upbeat outlook.
What To Know: Reddit recently posted first-quarter earnings of 13 cents per share, beating consensus estimates of 2 cents. Revenue hit $392.36 million, up from $242.96 million a year ago, driven by a 61% surge in ad revenue and a 31% increase in daily active users to 108.1 million. 
Net income <a href="https://www.benzinga.com/general/social-media/25/05/45178546/reddit-executives-see-strong-growth-in-q2-and-beyond">reached $26.2 million</a>, reversing a $575.1 million loss a year prior. Operating cash flow rose to $127.6 million, while gross margin improved to 90.5%.
Read Also: <a href="https://www.benzinga.com/general/sports/25/05/45424475/foot-locker-stock-soars-on-potential-dicks-sporting-goods-deal-report">Foot Locker Stock Soars On Potential Dick&#8217;s Sporting Goods Deal: Report</a>
CEO Steve Huffman touted weekly active users <a href="https://www.benzinga.com/general/social-media/25/05/45151798/reddit-stock-soars-after-better-than-expected-q1-daily-active-uniques-up-31-ad-revenue-up-61-and-more">exceeding 400 million</a>, and Reddit guided second-quarter revenue between $410 million and $430 million. Analysts responded positively: Seaport upgraded Reddit to Buy, Needham and JP Morgan raised their price targets, and consensus remains optimistic on long-term growth.
What Else: Meanwhile, the Kids Online Safety Act was <a href="https://www.theverge.com/news/666729/kids-online-safety-act-reintroduced">reintroduced</a> in the Senate this week. The bill would impose new safety requirements on platforms used by minors and has drawn both support and criticism, with tech firms like Apple Inc backing the measure and civil liberties groups voicing concern over potential censorship.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a>
<h2 class="wp-block-heading">How To Buy RDDT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Reddit&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RDDT has a 52-week high of $230.41 and a 52-week low of $49.13.

RDDT

Reddit (RDDT) Stock Is Down 9% Thursday: What's Going On?

Telsey Advisory Group analyst Dana Telsey maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and maintains $70 price target.

BIRK

Telsey Advisory Group Maintains Outperform on Birkenstock Holding, Maintains $70 Price Target

Click Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares are trading higher after the company announced it signed <a href="https://www.benzinga.com//node/45432200">a cooperation agreement</a> with Flash Mutal Technology.
What To Know: Click will work with Flash Mutual to jointly promote 24-hour instant device services for senior citizens in Hong Kong.
Flash Mutal, a company under Tencent's Sustainable Social Value initiatives, is a national high-tech enterprise headquartered in Guangdong, China. It aims to provide digital solutions to the elderly, students and the disabled.
The devices leverage AI to &#8220;offer round-the-clock smart monitoring for senior citizens to enhance their safety and to provide timely assistance when necessary.&#8221;
Click expects the partnership, together with the recently entered government-sponsored Community Care Service Voucher scheme for the elderly, to generate significant cross-selling synergies and boost revenue.
The stock is trading on higher-than-normal session volume at 349.71 million shares. The company&#8217;s average session volume over the past 100 days is 2.42 million shares, per data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro</a>.
Related Link: <a href="https://www.benzinga.com/news/earnings/25/05/45436534/walmart-doesnt-alter-annual-outlook-yet-ceo-says-all-tariffs-create-cost-pressures-but-china-has-biggest-impact">Walmart Doesn&#8217;t Alter Annual Outlook Yet, CEO Says &#8216;All Tariffs Create Cost Pressures But China Has Biggest Impact&#8217;</a>
CLIK Price Action: At the time of publication, Click shares are trading 163.1% higher at 73 cents, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
Image:

CLIK

Click Stock Is Soaring Thursday: What's Going On?

CRWV

CoreWeave shares are trading higher after the company entered in to an additional agreement with OpenAI. OpenAI has committed to pay the company up to $4.0 billion through April 2029 related to this agreement.

TOON

Kartoon Studios shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Cantor Fitzgerald analyst Jennifer Kim reiterates Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) from Overweight to Overweight.

BLTE

Cantor Fitzgerald Reiterates Overweight on Belite Bioto Overweight

BWS Financial analyst Hamed Khorsand maintains Hawkins (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWKN#NASDAQ">HWKN</a>) with a Buy and maintains $160 price target.

HWKN

BWS Financial Maintains Buy on Hawkins, Maintains $160 Price Target

ZEEKR Intelligent Technology Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)&nbsp;reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45427547/zeekr-group-reports-first-quarter-2025-unaudited-financial-results" rel="noreferrer noopener">fiscal&nbsp;first-quarter</a> results on Thursday. The company reported quarterly revenue of 22.02 billion&nbsp;Chinese yuan, representing&nbsp;an increase of&nbsp;1.1% year-on-year.
In U.S. dollars, revenue of $3.03 billion missed the analyst <a href="https://www.benzinga.com/earnings">consensus estimate of $3.90 billion</a>.
The&nbsp;Zeekr brand delivered 41,403 vehicles, an increase of 25.2%. Meanwhile, the Lynk &amp; Co brand delivered 72,608 vehicles, recording a growth of 18.9%, with 52.4% of deliveries coming from NEV models.
The premium electric vehicle company&#8217;s adjusted net loss per ADS was 2.33 Chinese yuan. In U.S. dollar terms, the company reported adjusted net loss per ADS of 32 cents.
Also Read: <a href="https://www.benzinga.com/25/03/44492590/alibaba-and-bmw-team-up-to-bring-ai-powered-smart-assistant-to-next-gen-cars-in-china" target="_blank" rel="noreferrer noopener">Alibaba, BMW Team Up To Bring AI-Powered Smart Assistant In Next-Gen China Cars</a>
Vehicle sales&nbsp;were&nbsp;19.1 billion&nbsp;Chinese yuan&nbsp;($2.63 billion) for the quarter, representing an increase of&nbsp;16.1%&nbsp;Y/Y driven by the increase in new model delivery volume, partially offset by the lower average selling price due to changes in product mix and pricing strategy.
The vehicle margin was&nbsp;16.5%, up from&nbsp;13.1%&nbsp;in the prior year quarter, driven by sustained cost-saving initiatives.
Revenues from other sales and services&nbsp;declined 45.2% Y/Y&nbsp;to $403 million for the quarter, mainly due to the decreased sales volume and unit price of battery packs and electric drives.&nbsp;
The gross margin expanded to&nbsp;19.1% for the quarter from&nbsp;16.3%&nbsp;a year ago. Adjusted net loss was $88 million for the quarter, down by 66.5%.
As of&nbsp;March 31, 2025, cash and cash equivalents and restricted cash&nbsp;stood at 9.9 billion Chinese yuan ($1.36 billion).
Jing Yuan, CFO, said, &#8220;In the first quarter of 2025, enhanced platform synergies and disciplined supply chain management drove record profitability, with our overall vehicle margin reaching 16.5% and the Zeekr brand&#8217;s margin rising to an unprecedented 21.2%.&#8221;
Price Action: ZK shares are trading lower 1.04% to $28.48 at the last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45238222/teslas-future-hinges-on-china-fsd-analyst-says" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Future Hinges On China FSD: Goldman Sachs</a></li>
</ul>
Image by aapsky via Shutterstock

Asia

Earnings

Zeekr Vehicle Sales Jump 25%, Cost Cuts Drive Record Margins

8691 Ashley Way Douglasville Ga LLC Shares of Beneficial Interest

Comments

ニュース

最新ニュース (LNAAS) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル